Potassium orotate - instructions for use, dose, side effects, contraindications

One tablet contains: active substance - potassium orotate 500 mg; Excipients: lactose monohydrate 66.0 mg, gelatin medical 3.0 mg, stearic acid 7.4 mg, potato starch to obtain tablets weighing 750.0 mg.

Description:

Round, flat cylindrical tablets of white color with a facet and a risk.

Pharmacotherapeutic group:Metabolic means

ATX: & nbsp

A.12.C.X Preparations of other minerals

Pharmacodynamics:

Orotic acid is one of the precursors of pyrimidine nucleotides that are part of the nucleic acids that are involved in the synthesis of protein molecules, and therefore, the salts of orotic acid are considered as anabolic agents and are used in the disturbances of protein metabolism to stimulate them. Usually potassium salt of orotic acid (potassium orotate) is used.Potassium orotate stimulates the synthesis of nucleic acids, the production of albumin in the liver (especially in conditions of prolonged hypoxia), increases appetite, has a diuretic, regenerating properties.

Pharmacokinetics:

After oral administration in the gastrointestinal tract, 10% of the dose taken internally is absorbed. In the liver turns into orotidin-5-phosphate.

It is excreted by the kidneys (30% in the form of metabolites).

Indications:

- As an auxiliary for diseases of the liver and biliary tract (caused by acute and chronic intoxication, with the exception of organic lesions of the liver and bile ducts);

- in the combination therapy of chronic heart failure and heart rhythm disturbances;

- alimentary and alimentary-infectious hypotrophy in children;

- chronic physical overstrain.

Contraindications:

Hypersensitivity to any of the components of the drug;

- acute and chronic organic liver damage;

- ascites;

- nefroourolithiasis;

- kidney failure;

- lactose intolerance;

- deficiency of lactase;

- glucose-galactose malabsorption;

- age up to 3 years.

Carefully:

During pregnancy and lactation.

Pregnancy and lactation:

The drug should be used with caution in pregnancy and lactation.

Dosing and Administration:

It should be taken orally 1 hour before meals or 4 hours after meals. Adults on 250-500 mg 2-3 times a day. The course of treatment lasts an average of 20-30 days. If necessary, treatment can be repeated after 1 month. AT

In exceptional cases, you can increase the dose of adults to 3 grams per day. Children - 10-20 mg / kg body weight per day, divided into 3-4 admission (for example, if the child's body weight is 25 kg, then the permitted dose is from 25 x 10 =

250 mg (1/2 tablets) to 25 x 20 = 500 mg (1 table per day, divided into 3-4 doses). The course of treatment is 3-5 weeks.

If symptoms persist, consult a physician.

Side effects:

Usually, potassium orotate is well tolerated. In some cases, allergic skin reactions may occur, which disappear after the interruption of treatment. Potassium orotate can also cause mild indigestion (nausea, vomiting). When used in high doses against the background of a low protein diet, it is possible to develop liver dystrophy.

If any side effects occur, consult a doctor.

Overdose:

Data on overdose are absent.

Interaction:

Potassium orotate somewhat reduces the toxicity of cardiac glycosides; the effect increases with its combination with magnesium preparations. Astringent and enveloping agents can somewhat reduce the absorption of potassium orotate in the gastrointestinal tract. Potassium orotate complicates the absorption of iron, tetracycline, sodium fluoride (the interval between taking the drug is at least 2-3 hours). Oral contraceptives, diuretics, muscle relaxants, glucocorticosteroids, insulin reduce the effect of the drug.

Special instructions:During the treatment period it is desirable to follow the diet.

Effect on the ability to drive transp. cf. and fur:

Does not cause drowsiness and reduce the speed of psychomotor reactions.

Form release / dosage:Tablets of 500 mg.

Packaging:

For 10 tablets in a contour non-cellular package made of paper with a polymer coating or from a material of a combined film croup.

For 10 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered. 10 tablets per contour cell packaging made of polyvinylchloride film and foil of aluminum printed lacquered and flexible packaging in rolls on the basis of aluminum foil for medicines.

For 10 or 20 tablets in a can of polymer or a bottle of polymer. Each jar or bottle, or 1, 2 or 3 contour squares, together with the instruction for use, is placed in a pack of cardboard.

100, 150 contour non-jammed packages or 100, 150 contour mesh packages together with the same number of instructions for use are placed in polyethylene film bags.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:4 years. Do not use after the expiration date stated on the package.

Terms of leave from pharmacies:Without recipe

Registration number:LS-000402

Date of registration:18.05.2010 / 29.02.2012

Expiration Date:Unlimited

The owner of the registration certificate:AVVA RUS, OJSC AVVA RUS, OJSC Russia

Manufacturer: & nbsp

AVVA RUS, OJSC Russia

Representation: & nbspAVVA ENG JSC AVVA ENG JSC Russia

Information update date: & nbsp26.11.2017

Illustrated instructions

Instructions

Potassium orotate (Potassium orotate)